170 related articles for article (PubMed ID: 20628376)
1. Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients.
Fajac A; Gligorov J; Rezai K; Lévy P; Lévy E; Selle F; Beerblock K; Avenin D; Saintigny P; Hugonin S; Bernaudin JF; Lokiec F
Br J Cancer; 2010 Aug; 103(4):560-6. PubMed ID: 20628376
[TBL] [Abstract][Full Text] [Related]
2. Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients.
Lévy P; Gligorov J; Antoine M; Rezai K; Lévy E; Selle F; Saintigny P; Lokiec F; Avenin D; Beerblock K; Lotz JP; Bernaudin JF; Fajac A
Breast Cancer Res Treat; 2013 Jun; 139(2):421-8. PubMed ID: 23666532
[TBL] [Abstract][Full Text] [Related]
3. Influence of ABCB1 C3435T and C1236T gene polymorphisms on tumour response to docetaxel-based neo-adjuvant chemotherapy in locally advanced breast cancer patients of South India.
Priyadarshini R; Raj GM; Kayal S; Ramesh A; Shewade DG
J Clin Pharm Ther; 2019 Apr; 44(2):188-196. PubMed ID: 30637776
[TBL] [Abstract][Full Text] [Related]
4. Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes.
Wu H; Kang H; Liu Y; Tong W; Liu D; Yang X; Lian M; Yao W; Zhao H; Huang D; Sha X; Wang E; Wei M
J Cancer Res Clin Oncol; 2012 Sep; 138(9):1449-62. PubMed ID: 22526155
[TBL] [Abstract][Full Text] [Related]
5. Association of plasma docetaxel levels with ABCB1 gene polymorphisms and tumour response in locally advanced breast cancer patients of South India on neo-adjuvant chemotherapy.
Priyadarshini R; Raj GM; Sundaram R; Kayal S; Ramesh A; Shewade DG
Breast Cancer; 2021 Mar; 28(2):414-423. PubMed ID: 33125673
[TBL] [Abstract][Full Text] [Related]
6. The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.
Chew SC; Singh O; Chen X; Ramasamy RD; Kulkarni T; Lee EJ; Tan EH; Lim WT; Chowbay B
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1471-8. PubMed ID: 21468756
[TBL] [Abstract][Full Text] [Related]
7. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
Tsai SM; Lin CY; Wu SH; Hou LA; Ma H; Tsai LY; Hou MF
Clin Chim Acta; 2009 Jun; 404(2):160-5. PubMed ID: 19332043
[TBL] [Abstract][Full Text] [Related]
8. MDRView: a visualization of the polymorphisms of MDR1(ABCB1) GENE in breast cancer.
Xhemo E; Fajac A; Boire JY; Levy P
Annu Int Conf IEEE Eng Med Biol Soc; 2007; 2007():4592-4. PubMed ID: 18003028
[TBL] [Abstract][Full Text] [Related]
9. ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
Sissung TM; Baum CE; Deeken J; Price DK; Aragon-Ching J; Steinberg SM; Dahut W; Sparreboom A; Figg WD
Clin Cancer Res; 2008 Jul; 14(14):4543-9. PubMed ID: 18628469
[TBL] [Abstract][Full Text] [Related]
10. ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy.
Kim HJ; Im SA; Keam B; Ham HS; Lee KH; Kim TY; Kim YJ; Oh DY; Kim JH; Han W; Jang IJ; Kim TY; Park IA; Noh DY
Cancer Sci; 2015 Jan; 106(1):86-93. PubMed ID: 25410489
[TBL] [Abstract][Full Text] [Related]
11. Association between ABCB1 C3435T polymorphism and breast cancer risk: a Moroccan case-control study and meta-analysis.
Tazzite A; Kassogue Y; Diakité B; Jouhadi H; Dehbi H; Benider A; Nadifi S
BMC Genet; 2016 Sep; 17(1):126. PubMed ID: 27580695
[TBL] [Abstract][Full Text] [Related]
12. ABCB1 genetic polymorphisms affect opioid requirement by altering function of the intestinal P-glycoprotein.
Qin W; Zhang L; Wang X; Liu B; Xu L; Liu L; Fan B
Biomed Pharmacother; 2024 Jul; 176():116897. PubMed ID: 38850645
[TBL] [Abstract][Full Text] [Related]
13. ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients.
Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Segura-Pérez AM; Chamorro-Santos C; Vergara-Alcaide E; Castillo-Portellano L; Calleja-Hernández MÁ
Pharmacol Res; 2016 Jun; 108():111-118. PubMed ID: 27137881
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy.
Knez L; Košnik M; Ovčariček T; Sadikov A; Sodja E; Kern I; Cufer T
J Cancer Res Clin Oncol; 2012 Sep; 138(9):1551-60. PubMed ID: 22543673
[TBL] [Abstract][Full Text] [Related]
15. Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis.
Yan M; Fan X; Si H; Wang X; Wang Z; Wang Z; Lv X; Yin H; Jia Y; Jiang L; Xia Y; Liu Y
Cancer Chemother Pharmacol; 2022 Feb; 89(2):173-181. PubMed ID: 34988655
[TBL] [Abstract][Full Text] [Related]
16. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients.
Lal S; Wong ZW; Sandanaraj E; Xiang X; Ang PC; Lee EJ; Chowbay B
Cancer Sci; 2008 Apr; 99(4):816-23. PubMed ID: 18377430
[TBL] [Abstract][Full Text] [Related]
17.
Chouchi M; Klaa H; Ben-Youssef Turki I; Hila L
Dis Markers; 2019; 2019():1343650. PubMed ID: 31871496
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.
Angelini S; Botticelli A; Onesti CE; Giusti R; Sini V; Durante V; Strigari L; Gentile G; Cerbelli B; Pellegrini P; Sgroi V; Occhipinti M; DI Pietro FR; Rossi A; Simmaco M; Mazzuca F; Marchetti P
Anticancer Res; 2017 May; 37(5):2633-2639. PubMed ID: 28476838
[TBL] [Abstract][Full Text] [Related]
19. Influence of (C1236T and C3435T) Polymorphisms of ABCB1 Gene on Chemotherapy Treatment Outcome and Toxicity in Breast Cancer Patients.
Gudur RA; Bhosale SJ; Gudur AK; Kale SR; More AL; Datkhile KD
Asian Pac J Cancer Prev; 2024 May; 25(5):1567-1577. PubMed ID: 38809628
[TBL] [Abstract][Full Text] [Related]
20. Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer.
Narita S; Tsuchiya N; Yuasa T; Maita S; Obara T; Numakura K; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Habuchi T
Int J Clin Oncol; 2012 Jun; 17(3):204-11. PubMed ID: 21706123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
